6533b824fe1ef96bd1280c30

RESEARCH PRODUCT

Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes

Helen K. ReddelHelen K. ReddelFanny W.s. KoFanny W.s. KoJiangtao LinJiangtao LinAziz SheikhAziz SheikhArzu YorganciogluArzu YorganciogluKevin MortimerKevin MortimerRoland BuhlRoland BuhlPaulo Márcio PitrezAlvaro A. CruzAlvaro A. CruzJerry A. KrishnanJerry A. KrishnanEric D. BatemanEric D. BatemanLouise FlemingLouise FlemingMark L. LevyGuy BrusselleGuy BrusselleHiromasa InoueHiromasa InoueLiesbeth DuijtsLiesbeth DuijtsJeffrey M. DrazenJeffrey M. DrazenJ Mark FitzgeraldJ Mark FitzgeraldLouis-philippe BouletChristopher E. BrightlingChristopher E. BrightlingLeonard B. BacharierLeonard B. Bacharier

subject

ExacerbationRespiratory SystemINHALED CORTICOSTEROIDSCritical Care and Intensive Care MedicineAsthma managementSINGLE-INHALERDOUBLE-BLINDRisk Factorsimmune system diseasesAdrenal Cortex HormonesRELIEVER THERAPYFormoterol FumarateMedicine and Health SciencesImmunology and AllergyAnti-Asthmatic AgentsChild11 Medical and Health SciencesLung functionMILD PERSISTENT ASTHMAExecutive summaryBiologic therapiesCombined Modality TherapyLUNG-FUNCTIONChild PreschoolPractice Guidelines as TopicPerspectiveDisease ProgressionDrug Therapy Combinationmedicine.drugPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyBUDESONIDE/FORMOTEROL MAINTENANCEAdolescentMild asthmaMEDLINEInhaled corticosteroidsCONTROLLED-TRIALSkills trainingGINA Strategy 2021: Executive SummaryBUDESONIDE-FORMOTEROLAdministration InhalationmedicineHumansasthma preventionIntensive care medicineSEVERE EXACERBATIONSAsthmaasthma diagnosisbusiness.industryPatient AcuityInfantasthmamedicine.diseaseAsthmarespiratory tract diseasesSelf Carewf_140Formoterolwf_100businessasthma management

description

Funder: Global Initiative for Asthma

10.1016/j.jaip.2021.10.001https://www.pure.ed.ac.uk/ws/files/241914809/Global_Initiative_for_Asthma_GINA_Strategy_2021_Executive_summary_and_rationale.pdf